title: Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma.
abstract: The combination of BRAF-targeted agents with immune checkpoint inhibitors represents a recent advance in the treatment of melanoma, even though each of these therapeutic approaches alone has specific limitations. Increasing evidence suggests indeed the existence of a synergistic interaction between these therapeutic modalities.
authors.affiliation: Division of Surgical Oncology; Massachusetts General Hospital; Boston MA USA.
authors.forename: Zachary A
authors.initials: ZA
authors.lastname: Cooper
authors.forename: Dennie T
authors.initials: DT
authors.lastname: Frederick
authors.forename: Zain
authors.initials: Z
authors.lastname: Ahmed
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Wargo
keywords: BRAF; PDL1; checkpoint blockade; immunotherapy; melanoma